Enfortumab Vedotin-Related Skin Toxicities: Insights From Clinical and Histopathological Analysis

IF 2.7 3区医学 Q2 DERMATOLOGY

Journal of Dermatology Pub Date : 2025-08-14 DOI:10.1111/1346-8138.17901

Yuki Kuma, Makiko Kido-Nakahara, Yoko Kuba-Fuyuno, Takashi Matsumoto, Yoshinao Oda, Masatoshi Eto, Takeshi Nakahara

引用次数: 0

Abstract

Enfortumab vedotin (EV), targeting Nectin-4, is effective in advanced urothelial carcinoma but frequently causes skin toxicities. This study examined the possible contribution of prior immune checkpoint inhibitor (ICI) therapy and higher EV doses to EV-related skin toxicity (EVST) development. Histopathological findings suggested both direct keratinocyte damage and immune-mediated mechanisms. These insights may improve clinical management of EVST.

Abstract Image

查看原文本刊更多论文

与维多素相关的皮肤毒性：来自临床和组织病理学分析的见解

针对Nectin-4的Enfortumab vedotin （EV）在晚期尿路上皮癌中有效，但经常引起皮肤毒性。本研究探讨了先前免疫检查点抑制剂（ICI）治疗和较高EV剂量对EV相关皮肤毒性（EVST）发展的可能贡献。组织病理学结果提示直接角质细胞损伤和免疫介导的机制。这些见解可能会改善EVST的临床管理。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Dermatology 医学-皮肤病学

CiteScore

4.60

自引率

9.70%

发文量

368

审稿时长

4-8 weeks

期刊介绍： The Journal of Dermatology is the official peer-reviewed publication of the Japanese Dermatological Association and the Asian Dermatological Association. The journal aims to provide a forum for the exchange of information about new and significant research in dermatology and to promote the discipline of dermatology in Japan and throughout the world. Research articles are supplemented by reviews, theoretical articles, special features, commentaries, book reviews and proceedings of workshops and conferences. Preliminary or short reports and letters to the editor of two printed pages or less will be published as soon as possible. Papers in all fields of dermatology will be considered.